Peptides DB
Research-centric peptide and protocol reference hub
7–14 September 2026 · updated 7 days ago

The Research Briefing — 29 new studies this week

Everything filed, reported or changed in the last seven days, in one place. Studies carry the grade they contribute, headlines link to the outlet, and every change to our own pages is listed rather than quietly applied.

Get this page by email

Written by the Librarian every Monday from that week’s filed studies. No sponsorships, one click out.

73
Studies filed
33
With human data
8
Headlines
—
Grade moved
2
Tracker points expired
368
Agent actions
Story of the weekBMJ (Clinical research ed.) · grade B

Reverse total shoulder replacement versus anatomical total shoulder replacement for osteoarthritis: population based cohort study using data from the National Joint Registry and Hospital Episode Statistics for England.

Not reported in abstract.

—
Participants
—
Trial phase
B
Evidence grade
0.10
AI confidence
Why it leads

Top-journal study · Human study — the highest-scoring filing indexed this week.

Read our analysis →

Studies filed

73 this week · 33 with human data · sorted by the grade they contributeOpen the research library →
AThe Effect of Intrauterine Oxytocin-Soaked Gauze on Postoperative Bleeding in Cesarean Section: A Double-Blind Randomized Clinical Trialbiorxiv-preprint · RCTMedian blood loss was 440 mL [IQR 350–530] in the oxytocin group compared with 540 mL [420–625] in the saline group and 625 mL [475–700] in the control group; p<0.001.OxytocinNeuro & moodMon 06:07AOromucosal administration of oxytocin and its receptor antagonist atosiban respectively increase and decrease preferential attention to dynamic social stimuli in menbiorxiv-preprint · RCT48 IU oxytocin significantly increased preferential viewing of social stimuli relative to placebo, n=250.OxytocinNeuro & moodMon 06:07ASurvodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · RCT · phase 384.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC, P<0.0001.Survodutide (BI 456906)Metabolic & appetiteMon 06:01ASurvodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · RCT-12.2% mean change in body weight from baseline in the 3.6-mg group at week 76, 95% CI -13.6 to -10.8.Survodutide (BI 456906)Metabolic & appetiteMon 06:01AAuthor Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · phase 3Survodutide (BI 456906)Metabolic & appetiteMon 06:01
All 73 filings68 more filed this week

What changed on this site

4 pages · every change dated and reversibleFull change log →
Content refreshMon · Site
Re-verified tracker: Compounded GLP-1 Legal Status

The legality of compounded GLP-1 drugs remains tightly restricted following the removal of both semaglutide and tirzepatide from the FDA shortage list. · Item updates applied: 4 · Status label → Restricted · Status tone → red

See the reasoning →
Content refreshMon · Site
Re-verified tracker: Retatrutide FDA Approval Tracker

Retatrutide remains in Phase 3 development with no updates on approval status. · Item updates applied: 0 · Status label → Not approved — Phase 3 · Status tone → amber

See the reasoning →
Content refreshMon · Site
Re-verified tracker: GLP-1 Availability & Access (2026)

No significant changes in availability or access noted since the last review. · Item updates applied: 0 · Status label → Access to GLP-1 drugs remains limited · Status tone → amber

See the reasoning →
Content refreshMon · Site
Re-verified tracker: Compounded GLP-1 Legal Status

The legality of compounded GLP-1 drugs remains tightly restricted following the removal of semaglutide and tirzepatide from the FDA shortage list. · Item updates applied: 4 · Status label → Restricted · Status tone → red

See the reasoning →

In the news

8 headlines from 32 monitored outletsNewswire →

Community pulse

Anecdotal · not evidencer/Semaglutide · past 7 days
On my way to success!r/SemaglutideSep 20Favorite thingsr/SemaglutideSep 20Just a repostr/SemaglutideSep 18Our monthly shopping bill for food is down by 80%r/SemaglutideSep 17

Included for sentiment, never as evidence: self-selected, unverified, no denominator. They do not affect any grade on this site.

Educational use only — not medical advice

Many peptides covered here are not approved for human use and are sold strictly for research. Nothing on this page is diagnosis, treatment, or a recommendation. Consult a licensed clinician before any decision about your health, and see our editorial policy and AI disclosure for how these items are sourced and summarised.